CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) Fell 15.30% to 88.940
Newtimespace News, as of 13:24 on May 14, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) was quoted at HKD 88.940, down 15.30%. The product opened at HKD 103.800, with a high of HKD 104.000 and a low of HKD 87.900. The latest Net Asset Value (NAV) per unit is HKD 103.023, with a premium rate of 1.92%. The asset size is approximately HKD 56.809 billion.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) is a Leveraged and Inverse Product issued by CSOP Asset Management, primarily tracking the share price performance of the South Korean individual stock SK Hynix. The product employs a synthetic replication strategy using swaps, with the investment objective of providing, before fees and expenses, investment returns equivalent to two times (2x) the daily performance of SK Hynix ordinary shares. SK Hynix is a global leading semiconductor manufacturer holding a core position in the Dynamic Random-Access Memory (DRAM) and NAND flash memory markets. Its share price movement is highly correlated with the global semiconductor industry cycle and the demand for Artificial Intelligence (AI) computing power.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- KNOWLEDGE ATLAS(02513.HK) closed 19.29% lower, closing at HKD 1640
- TAN CHONG INT'L (00693.HK): Expected Unrealised Investment Loss of HK$512 Million for First Half Due to Share Price Movements of Listed Investments
- SBP GROUP (01177.HK): NDA Accepted for Category 1 Innovative Drug IDH1 Inhibitor TQB3454 for Advanced Biliary Tract Cancer
- Pizu Group(09893.HK): Change of Independent Non-executive Director, Appointment of Wei Lai
- DUFU LIQUOR GP (00986.HK): Li Jingfu Appointed CEO of Subsidiary to Lead Research on AI Digital Human and Internet Marketing Business